Overlooked Stock: TEVA
- Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can be the first step in a turnaround for the company.
- 12/17/2024
|
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
- U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn's disease.
- 12/17/2024
|
TD says Spyre has 'superior TL1A program' after Teva data
- TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the "superior TL1A program" and its combination treatments under development "will further elevate outcomes." Teva and Sanofi's results "further validate TL1A inhibition as a highly promising mechanism" for both ulcerative colitis and Crohn's disease, contends the firm. Spyre Therapeutics +0.105 (+0.43%) Teva +4.32 (+26.18%) Sanofi +3.38 (+7.37%)
- 12/17/2024
|
Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
- BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in development and launch milestones. The firm's "main takeaways" for Spyre Therapeutics (SYRE) from today's update from Teva are that strong market demand for anti-TL1A assets has "not faded at all" and the upside potential for SPY002 "looks even further reinforced," as BTIG expects the TL1A constructs that Spyre is developing to "likely leapfrog the broader class both on efficacy and dosing." The firm, which keeps a Buy rating and $70 price target on Spyre shares, views the relative weakness following the duvakitug data as a buying opportunity, the analyst tells investors. Spyre Therapeutics -0.005 (-0.02%) Teva +4.385 (+26.58%)
- 12/17/2024
|
Teva price target raised to $25 from $23 at BofA
- BofA raised the firm's price target on Teva to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the strong Phase 2 update for duvakitug as a treatment for inflammatory bowel disorders, the analyst tells investors in a research note. The firm now forecasts nominal peak sales of roughly $2B, with Teva booking half the profits, based on the strength of the data and the emerging product profile.
- 12/17/2024
|
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
- Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
- 12/17/2024
|
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical
- Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today.
- 12/17/2024
|
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
- On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
- 12/17/2024
|
Teva, Sanofi say drug to treat IBD met primary targets
- Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
- 12/17/2024
|
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
- Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- 12/17/2024
|
Can Teva Return To All-Time Highs?
- Teva Pharmaceutical stock has rebounded from lows, driven by debt reduction, halted price deflation in generics, and new product launches, making it a strong buy. Teva's innovative branded drugs and biosimilar pipeline, including AUSTEDO and upcoming biosimilars like PROLIA and RANIVISIO, offer substantial growth opportunities. Teva's business has followed a boom and bust cycle. Substantial biologic patent expirations in the coming years point to another boom.
- 12/06/2024
|
Pharma firm Teva to divest its business venture in Japan
- Teva Pharmaceutical Industries said on Thursday it will transfer ownership of its business venture that sold generics in Japan to JKI.
- 12/05/2024
|
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
- TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
- 12/05/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 5, 2024 8:20 AM ET Company Participants Richard Francis - President and Chief Executive Officer Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Thank you, guys for being here. Super excited to have Teva management.
- 12/05/2024
|
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
- TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.1 The trial showed statistically significant superior efficacy compared to placebo over 12 weeks with a favourable safety profile1 consistent with that observed in the adult population.
- 12/04/2024
|
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
- Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
- 11/28/2024
|
2 Generic Drug Stocks Ready to Surge in 2025
- Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials.
- 11/27/2024
|
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
- TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva's Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time.
- 11/25/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Jefferies London Healthcare Conference November 19, 2024 3:30 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Good morning, everyone. Thanks for joining us.
- 11/19/2024
|
Teva to Present at the Jefferies London Healthcare Conference
- TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time).
- 11/08/2024
|
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 11/08/2024
|
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
- TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.
- 11/07/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head of R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Umer Raffat - Evercore ISI Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schott - J.P. Morgan Ash Verma - UBS Yifeng Liu - HSBC Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings Conference Call.
- 11/06/2024
|
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 11/06/2024
|
Teva Pharm CEO says will work productively with Trump administration
- Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday.
- 11/06/2024
|
Teva Pharmaceutical third-quarter profit, revenue top estimates
- Teva Pharmaceutical Industries reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease.
- 11/06/2024
|
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
- For an accessible version of this Press Release, please visit www.tevapharm.com
- 11/06/2024
|
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
- Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
- 11/05/2024
|
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Teva Pharmaceutical Industries (TEVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 11/04/2024
|
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
- TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.
- 11/01/2024
|
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
- TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.
- 11/01/2024
|
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 11/01/2024
|
Teva Statement on European Commission Decision; Company to Appeal
- TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company's practices regarding COPAXONE® -- the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed.
- 10/31/2024
|
Teva fined $503 mln by EU for disparaging rival product
- The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone, confirming a Reuters exclusive.
- 10/31/2024
|
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Teva Pharmaceutical Industries (TEVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 10/25/2024
|
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
- Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
- 10/23/2024
|
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/23/2024
|
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
- Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend.
- 10/23/2024
|
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
- REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara® (ustekinumab) in the U.S. at launch, which is expected in the first quarter of 2025.
- 10/22/2024
|
3 Attractive Biotechs With Recent Positives
- The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
- 10/21/2024
|
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
- Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
- 10/18/2024
|
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
- On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
- 10/17/2024
|
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
- New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday.
- 10/10/2024
|
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
- TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1
- 10/08/2024
|
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
- Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
- 10/07/2024
|
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/07/2024
|
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
- TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.
- 10/03/2024
|
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
- PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.
- 10/01/2024
|
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
- TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
- 09/30/2024
|
Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia
- MONTPELLIER, France--(BUSINESS WIRE)--Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia. Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and secondary endpoints of the SOLARIS study, the data presented by Teva unveiled the three doses evaluated, which align wit.
- 09/23/2024
|
Medincell's Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
- MONTPELLIER, France--(BUSINESS WIRE)--New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified. Perseris manufacturer announced in July 2024 the discontinuation of its commercialization. Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY f.
- 09/23/2024
|
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
- TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia (TD) was associated with long term improvement of TD symptoms. The improvement in symptoms was sustained throughout the three-year study, and deutetrabenazine was well tolerated.1 The data were presented at the European College of Neuropsychopharmacology (ECNP) annual congress in Milan.
- 09/23/2024
|
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
- TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. In the study, TEV-‘749 met the primary endpoint, demonstrating significant improvements in the Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 8, as well as key secondary endpoints with improvements in both the Clinical Global Impression-Severity (CGI-S) scale and the Personal and Social Performance (PSP) scale score, compared to placebo at week 8. Additionally, SOLARIS (Period 1) and Phase 1 safety results demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) in participants taking TEV-‘749 to date.1 The overall safety profile was consistent with other oral acting olanzapine options. These data were presented during the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress taking place between September 21-24, 2024, in Milan, Italy.
- 09/21/2024
|
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
- TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today presented data informing clinical strategies for switching patients to UZEDY®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly subcutaneous injection of Perseris ® (RBP-7000). The results were presented during the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress taking place between September 21-24, 2024, in Milan, Italy.
- 09/21/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
- Teva Pharmaceuticals Industries Limited (NYSE:TEVA ) Bank of America Global Healthcare Conference September 18, 2024 3:15 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Thank you, Richard, for joining us here at the BofA Global Healthcare Conference in London. My name is Jason Gerberry.
- 09/19/2024
|
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
- Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
- 09/13/2024
|
Teva to Present at the Bank of America 2024 Global Healthcare Conference
- TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time).
- 09/11/2024
|
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
- Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
- 09/10/2024
|
Exclusive: Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
- Teva , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.
- 09/10/2024
|
Cheap Teva Stock Should Reward Patient Investors
- Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is likely to manage effectively. Teva's generic drug revenue surged 16% in Q2, and the unit's continued growth is expected to significantly boost the firm's overall revenue.
- 09/09/2024
|
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
- JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
- 09/06/2024
|
Medincell's Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
- MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results are expected to be available in H2 24. Olanzapine LAI is an investigational once-monthly subcutaneous long-acting.
- 09/05/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 4, 2024 11:30 AM ET Company Participants Richard Francis - Chief Executive Officer Conference Call Participants Thibault Boutherin - Morgan Stanley Thibault Boutherin So, good morning, everyone, and thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutherin.
- 09/04/2024
|
2 Reasonably Priced Stocks to Keep an Eye On
- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Hewlett Packard Enterprise Co (NYSE:HPE) are this week's picks for Schaeffer's Cheap Seats : Stocks Under $20 segment.
- 08/29/2024
|
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time.
- 08/26/2024
|
Teva's Transformation: From Generics Leader To Branded Drug Innovator
- Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy.
- 08/14/2024
|
The 7 Best Under $20 Stocks to Buy in August 2024
- Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.
- 08/07/2024
|
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
- Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.
- 08/02/2024
|
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
- TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook.
- 08/01/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head, R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Ash Verma - UBS Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Omri Efroni - Oppenheimer Umer Raffat - Evercore Glen Santangelo - Jefferies Chris Schott - J.P. Morgan Yifeng Liu - HSBC Operator Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q2 2024 Earnings Call.
- 07/31/2024
|
Teva Pharma CEO: Majority of momentum came from innovative business, not GLP-1s
- Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.
- 07/31/2024
|
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 07/31/2024
|
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 07/31/2024
|
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
- Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 07/29/2024
|
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
- Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and generics, positive data on Uzedy and Ajovy, and an accelerated timeline for TEV-48574. Financially, Teva's current ratio is under 1, with upcoming debt maturities posing a challenge. Recommendation remains "Hold" pending Q2 earnings.
- 07/26/2024
|
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
- TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
- 07/19/2024
|
3 No-Brainer Stocks to Buy With $200 Right Now
- There's never a bad time to put your money to work on Wall Street if you have a long-term mindset. A majority of online brokers have eliminated commission fees on common stock trades and minimum deposit requirements, which is great news for retail investors.
- 07/17/2024
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
- 07/10/2024
|
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
- Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year.
- 07/10/2024
|
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call wil.
- 07/02/2024
|
Teva's stock falls after report FTC has opened probe of patents
- Teva Pharmaceuticals Industries Ltd.'s stock fell 2% Monday after a report said the Federal Trade Commission has opened an investigation into the Israeli generics company, citing its refusal to take down roughly two dozen patents for its asthma and COPD inhalers.
- 07/01/2024
|
FTC starts probe into Teva about some products' patents, Washington Post reports
- The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
- 07/01/2024
|
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its com.
- 06/25/2024
|
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
- Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
- 06/24/2024
|
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
- PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States. “By launching an authorized generic for Victoza® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Te.
- 06/24/2024
|
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
- Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.
- 06/13/2024
|
Teva Pharmaceutical: Buy This Bargain Before It's Gone
- Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter of 2024. Austedo/Austedo XR sales totaled $282 million in the first three months of 2024, up 65.9% yearly, thanks to its competitive advantage in the fast-growing tardive dyskinesia therapeutics market.
- 06/07/2024
|
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be av.
- 06/04/2024
|
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
- TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
- 06/04/2024
|
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
- TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophren.
- 06/01/2024
|
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
- TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients' quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30.
- 06/01/2024
|
2 Generic Drug Makers With Growing Runways
- Brand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and patients as they contain the same compounds and active ingredients for a cheaper price.
- 05/31/2024
|
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
- Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.
- 05/16/2024
|
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership T.
- 05/15/2024
|
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) BofA Securities 2024 Health Care Conference May 14, 2024 11:40 AM ET Company Participants Jason Gerberry - Managing Director, US Specialty Pharma and Smid Cap Biotech Richard Francis - President & CEO Eric Hughes - EVP, Global R&D & CMO Conference Call Participants Jason Gerberry
- 05/14/2024
|
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 05/13/2024
|
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
- Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction, and improved guidance pointing to additional upside.
- 05/10/2024
|
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
- TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
- 05/09/2024
|
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/08/2024
|
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
- Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released positive late-stage trial data on a schizophrenia treatment.
- 05/08/2024
|
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
- Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
- 05/08/2024
|
Teva Pharm Q1 profit falls short of estimates, revenue gains
- Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.
- 05/08/2024
|
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024. Mr. Richard Francis, Teva's President and CEO, said, "In 2024 Teva is off to a good start, with global revenues of $3.8 billion showing growth of 5% in local currency terms compared to Q1 2023, fueled by robust growth in our generics business across all regions, and continued growth of our innovative brands AUSTEDO and AJOVY." Mr. Francis cont.
- 05/08/2024
|
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
- Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.
- 05/08/2024
|
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
- PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--ACCESS HERE THE COMPLETE PRESS RELEASE Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpo.
- 05/08/2024
|
Teva Earnings Are Coming. What Could Keep the Stock Gains Going.
- The pharmaceutical company reports before the market open Wednesday.
- 05/07/2024
|
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
- Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
- 05/06/2024
|
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
- Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 05/03/2024
|
Teva to Present at the 2024 Bank of America Healthcare Conference
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webca.
- 05/02/2024
|
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva's operations and value chain by 2045 and 100% renewable electricity across all Teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity buil.
- 05/02/2024
|
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
- The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.
- 04/30/2024
|
You Would Fire “God” As Your Portfolio Manager
- Investors are growing nervous
- 04/23/2024
|
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
- 04/18/2024
|
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will b.
- 04/09/2024
|
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
- Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.
- 04/01/2024
|
6 reasons to buy Teva Pharmaceuticals stock sooner than later
- Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.
- 02/26/2024
|
Teva Pharm to stay as unified generics, branded drugmaker, CEO says
- Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard Francis said on Tuesday.
- 02/20/2024
|
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
- TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
- 02/01/2024
|
Teva's CEO talks Q4 earnings and how he is implementing his 'pivot to growth' strategy
- Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy.
- 01/31/2024
|
Teva Pharma CEO Richard Francis on Q4 earnings
- Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.
- 01/31/2024
|
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 01/31/2024
|
Teva to divest active pharmaceutical ingredient business
- Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.
- 01/31/2024
|
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
- 01/26/2024
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
- 01/25/2024
|
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/25/2024
|
Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript)
- Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript)
- 01/09/2024
|
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free p.
- 01/02/2024
|
Small mid cap biotech, pharma stocks set for better 2024: analysts
- Small cap and mid cap biotech and speculative pharma stocks have a more constructive outlook heading into 2024, relative to previous years, but the idiosyncratic nature of the space continues to put a premium on stock picking, according to Bank of America analysts. In an update to clients, the analysts noted that they remain encouraged by sector fundamentals, including research and development (R&D) output and external demand for biotech innovation as measured by merger and acquisition (M&A) trends.
- 01/02/2024
|
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
- Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said Teva does not infringe any asserted claims of Corcept's US Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering its flagship Korlym drug with drugs that are strong inhibitors of CYP3A4, an enzyme mainly found in the liver and the intestine.
- 01/02/2024
|
Corcept stock drops after drugmaker loses patent lawsuit against Teva
- Corcept Therapeutics Inc. shares CORT, -1.22% dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva Pharmaceutical Industries Ltd. TEVA, -0.29%.
- 01/02/2024
|
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the.
- 12/28/2023
|
Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz
- Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.
- 12/20/2023
|
Indivior settles patent wrangle with Teva subsidiary
- Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals. The disagreement was about Actavis's plan to make a generic version of a drug combining buprenorphine and a naloxone sublingual film.
- 12/20/2023
|
Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
- I am upgrading Teva Pharmaceutical to "Buy" for 2024, buoyed by opioid litigation resolution and promising drugs like TEV'574. Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, and Uzedy, and increased R&D investment. TEV'574, in collaboration with Sanofi, shows significant promise in inflammatory bowel disease treatment, enhancing TEVA's pipeline.
- 12/08/2023
|
Teva Pharma is the way to play the re-rise of generic drugs
- Generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd. NYSE: TEVA stock has underperformed for nearly a decade.
- 11/28/2023
|
Teva Pharmaceutical analysts boost target price as brand transition underway
- Teva Pharmaceutical Industries (NASDAQ:TEVA) Ltd is uniquely positioned to undergo a significant transition to a more brand focused company that should drive outperformance of its stock price, according to UBS analysts. In an update to clients, they upgraded Teva stock to ‘Buy' from ‘Neutral', while raising its price target by 37% to $13 per share, believing the stock is not pricing in the company's brand transition.
- 11/27/2023
|
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 2.
- 11/20/2023
|
2 overlooked stocks that crushed earnings but traded lower
- As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings season has its share of misfits and heroes.
- 11/20/2023
|
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
- TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.
- 11/09/2023
|
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
- Teva Pharmaceutical Industries (NYSE:TEVA ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Investor Relations Richard Francis - President and Chief Executive Officer, Member of the Board of Directors Eric Hughes - Executive Vice President, Global R&D and Chief Medical Officer Eli Kalif - Executive Vice President, Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Nathan Rich - Goldman Sachs Glen Santangelo - Jefferies David Amsellem - Piper Sandler Operator Hello, and welcome to the Q3 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex.
- 11/08/2023
|
Teva shares climb as third-quarter sales top estimates
- Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA, -0.11% gained 3% premarket on Wednesday after the company reported third-quarter sales that topped expectations and raised its full-year revenue guidance.
- 11/08/2023
|
Teva Pharm Q3 profit rises, sees higher 2023 revenue
- Teva Pharmaceutical Industries reported slightly higher third-quarter profit, helped by sales of its Austedo treatment for Huntington's Disease, and said production in Israel was unaffected by the country's war with Hamas in Gaza.
- 11/08/2023
|
Drugmaker Teva does not see big impact on business from Israel-Hamas war
- Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday.
- 10/10/2023
|
Israeli Stocks Fall as Investors Fear Middle East Conflict
- Two days ago, the Palestinian militant group Hamas launched a full-scale attack on Israel from the Gaza Strip. Since then, a full-scale conflict has escalated with many civilian casualties.
- 10/09/2023
|
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
- Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
- 10/09/2023
|
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, November 8, 2023, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available.
- 10/06/2023
|
Teva partnership with Sanofi ‘will pay dividends,' analyst says
- Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI analysts wrote in a note Wednesday, as the companies team up on a therapy that's drawing growing investor interest.
- 10/04/2023
|
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drug
- Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately be a blockbuster drug.
- 10/04/2023
|
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
- Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.
- 09/26/2023
|
TEVA: A Pharmaceutical Stock to Watch Right Now
- Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure, we are positioned in.
- 09/12/2023
|
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 8:40 AM ET Company Participants Richard Francis - Chief Executive Officer Conference Call Participants Thibault Boutherin - Morgan Stanely Thibault Boutherin So, good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference.
- 09/11/2023
|
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available.
- 09/06/2023
|
Alkermes shares surge after settlement with Teva on alcohol dependence treatment
- Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivitrol, a treatment for alcohol and opioid dependence. The settlement agreement, which will be submitted for regulatory review, gives Teva a license to market a generic version of Vivitrol in the U.S. starting in early 2027, Alkermes said in a release.
- 08/30/2023
|
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
- On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. Teva Pharmaceutical's revenue for the second quarter of 2023 was $3.88 billion, up 6% from the previous quarter and up 2.4% from the second quarter of 2022. TEV-48574 is a key gem in the company's portfolio, which is being developed for treating inflammatory bowel disease and continues to demonstrate excellent efficacy in vitro studies.
- 08/26/2023
|
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
- TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
- 08/23/2023
|
TEVA to Pay $250 Million to Settle Price-Fixing Charges
- TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
- 08/22/2023
|
Teva Pharma lands US$225 million fine for price-fixing
- Generic drug maker Teva Pharmaceuticals is to pay US $225 million in fines after admitting price-fixing on a range of drugs in the US. Teva and another firm it worked with, Glenmark Pharmaceuticals, have received deferred prosecution agreements, so as to avoid a trial or criminal prosecution.
- 08/22/2023
|
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges
- Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholestoral to settle price-fixing charges from the US Department of Justice, the agency announced Monday.
- 08/21/2023
|
DOJ orders Teva and Glenmark to pay millions in fines in drug price fixing settlment
- CNBC's Bertha Coombs joins 'Closing Bell Overtime' with breaking news on the DOJ's antitrust agreement involving Teva and Glenmark.
- 08/21/2023
|
Teva Pharmaceuticals agrees to pay $225 million fine to settle price-fixing charges
- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, +0.52%, said Monday that it has reached an agreement with the U.S. Department of Justice to settle criminal price-fixing charges brought against the company in 2020.
- 08/21/2023
|
Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges
- It's the latest resolution in a string of cases related to price-fixing, referring to competitors banding together to artificially set the price of a product.
- 08/21/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
- 08/11/2023
|
Teva agrees to pay $126 mln to US hospitals over opioids
- Teva Pharmaceutical Industries Ltd has agreed to pay up to $126 million to U.S. hospitals over 18 years to settle claims that its marketing of opioid drugs raised the hospitals' operating costs.
- 08/03/2023
|
Teva Pharm CEO: Not too late to launch Humira biosimilar in 2024
- Teva Pharmaceutical Industries , will still pursue launching a biosimilar for arthritis drug Humira next year despite a crowded marketplace, chief executive Richard Francis said on Wednesday.
- 08/02/2023
|
Teva CEO Richard Francis on Q2 earnings beat
- Teva CEO Richard Francis joins 'Squawk on the Street' to discuss their Q2 earnings, what's next for the company, and more.
- 08/02/2023
|
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
- The headline numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/02/2023
|
Teva Pharmaceutical Q2 profit tops estimates, Huntington's drug sales jump
- Teva Pharmaceutical Industries reported higher than expected second-quarter profit boosted by a jump in sales of its Austedo treatment for Huntington's Disease.
- 08/02/2023
|
Teva Pharmaceuticals and Alvotech expand biosimilars partnership
- Teva Pharmaceuticals Industries Ltd. TEVA, +0.47% and Alvotech ALVO, +0.51% announced Monday that they are expanding their collaboration in the U.S. biosimilars market.
- 07/24/2023
|
Teva Pharmaceutical's Remarkable Growth In 2023: A Success Story
- On August 2, 2023, Teva Pharmaceutical, one of the world's top generic drug manufacturers, will publish its financial report for the second quarter of 2023. The company has launched generic versions of several medicines and is conducting phase 2 trials for TEV-48574, an experimental drug for moderate to severe ulcerative colitis or Crohn's disease. Despite an agreement with Nevada, Teva's share price has dropped over 15% since the start of 2023, underperforming competitors like Dr. Reddy's Laboratories and Viatris.
- 07/20/2023
|
Teva Pharmaceuticals upgraded with improving product mix set to bolster gross margins
- Analysts at UBS have upgraded their rating on Teva Pharmaceuticals, a manufacturer of generic pharmaceuticals, to ‘Neutral' from ‘Sell' citing a now balanced risk/reward profile. They also raised their price target from US$7 to US$8.
- 07/06/2023
|
Teva considers sale of its active ingredients unit: Bloomberg
- Shares of Teva are fluctuating after a report from Bloomberg that the company is considering a sale of its active ingredients business. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the story.
- 07/06/2023
|
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available o.
- 07/05/2023
|
5 Well-Known Buy-Rated Stocks Under $10 Could Explode Higher in July
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 06/24/2023
|
3 Bargain Stocks to Buy on the Dip
- Bristol Myers Squibb stock is too cheap to ignore. Pfizer has more good news on the way than meets the eye.
- 06/17/2023
|
NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan
- New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.
- 06/09/2023
|
Teva Pharmaceutical settles $193M opioid suit with the state of Nevada
- Teva Pharmaceutical Industries (NASDAQ:TEVA) has agreed to pay the state of Nevada $193 million to settle claims that its marketing efforts helped fuel opioid addiction, the state announced Wednesday. Nevada was one of just two states not part of the $4.35 billion national settlement with the Israel-based company in 2022.
- 06/08/2023
|
Teva concludes nationwide opioid settlement agreement, reaches separate settlement with Nevada
- Teva Pharmaceuticals TEVA, +2.07% announced Thursday that it has resolved its nationwide settlement agreement related to opioid claims brought by states and reached a separate settlement with the state of Nevada. The company will pay Nevada $193 million over 20 years, resolving the case ahead of a trial that was set to start in August.
- 06/08/2023
|
Teva to pay Nevada $193 million over role in opioid epidemic
- Teva Pharmaceutical Industries on Wednesday agreed to pay Nevada $193 million to settle claims that its marketing practices fueled opioid addiction, the state announced.
- 06/07/2023
|
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
- Teva is refocusing its efforts on biosimilar medicines and cost-cutting. It's also looking to broaden its pipeline more generally to develop more generics.
- 06/05/2023
|
5 Very Well Known Buy-Rated Stocks Under $10 Could Explode Higher This Summer
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 05/27/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 05/23/2023
|
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual Meeting
- TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its neuroscience portfolio will be presented during the American Psychiatric Association's (APA) 2023 Annual Meeting taking place on May 20-24, 2023. Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for th.
- 05/20/2023
|
Teva Will Slim Down Its Generic Drug Business
- The new corporate strategy aims to deliver a “pivot to growth," the drugmaker said.
- 05/18/2023
|
Why Teva Pharmaceutical Stock Is Jumping Today
- Teva announced a new growth strategy. This news sparked an upgrade of the pharma stock by one analyst.
- 05/18/2023
|
Why Is Teva Pharmaceuticals (TEVA) Stock Up Today?
- Teva Pharmaceuticals (NYSE: TEVA ) stock is climbing higher on Thursday after the pharmaceutical company announced a new growth strategy. Teva Pharmaceuticals has laid out the four pillars of how it plans to grow with its new plan.
- 05/18/2023
|
Teva Pharmaceutical announces new growth strategy built on biosimilars, innovation
- Teva Pharmaceutical Industries on Thursday launched a new “pivot to growth” strategy, based on existing growth drivers like Austedo and Ajovy as well as generics, further innovation, and focused capital allocation. The company expects annual sales of more than $2.5 billion by 2027 for Austedo, which treats involuntary movements associated with Huntington's disease.
- 05/18/2023
|
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales
- Teva Pharmaceutical reported lighter-than-expected earnings for the first quarter, leading Teva stock to plunge early Wednesday. The post Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales appeared first on Investor's Business Daily.
- 05/10/2023
|
Teva Pharmaceutical Is Stabilizing Hinting A Payoff Potential
- Teva Pharmaceutical Is Stabilizing Hinting A Payoff Potential.
- 04/25/2023
|
Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread
- Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread
- 04/18/2023
|
1 "Safe" Stock to Avoid and 1 to Consider Buying in April
- In theory, the stock of companies that make generic drugs have the potential to be safe investments. Despite that, companies like Teva Pharmaceuticals aren't actually safe at all.
- 04/15/2023
|
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
- 04/14/2023
|
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 04/14/2023
|
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
- Millions of people are scrambling to navigate the Adderall shortage in a saga closely watched by investors in Teva and other drug stocks. Here's what you should know.
- 04/05/2023
|
Generic drugs are most likely to face shortages due to market failures in affordability
- CNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
- 03/29/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
7 Strong Buy Stocks Under $10 to Snap Up Now
- Investors looking for a bargain and potential upside have strong buy stocks under $10 to consider. Investors should snap up companies that have value without sacrificing quality or growth.
- 03/23/2023
|
Better Generics Pharmaceutical Stock: Teva or Viatris?
- Teva is the world's largest maker of generic drugs. Viatris offers an above-average dividend yield.
- 03/05/2023
|
3 Generic Drug Stocks to Watch Amid Macro Headwinds
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
- 03/03/2023
|
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
- Dear Investor:
- 02/22/2023
|
Competition Coming For AbbVie's Blockbuster Humira
- It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
- 02/16/2023
|
What To Expect From Teva Pharmaceutical In 2023 With A New CEO
- Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even though Copaxone sales declined.
- 02/15/2023
|
Top Trades of David Abrams' Firm in the 4th Quarter
- David Abrams (Trades, Portfolio), founder of Abrams Capital Management, disclosed in a regulatory portfolio update filing that his firm's top trades during the fourth quarter included the transfer of its U-Haul Holding Co. ( UHAL , Financial)( UHAL.B , Financial) holding from voting shares to non-voting shares. The firm also boosted its position in Meta Platforms Inc. ( META , Financial), exited its positions in O-I Glass Inc. ( OI , Financial) and Kinder Morgan Inc. ( KMI , Financial) and trimmed its holdings in TransDigm Group ( TDG , Financial) and Teva Pharmaceutical Industries ( TEVA , Financial).
- 02/13/2023
|
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
- Axsome Therapeutics (NASDAQ: AXSM ) stock is taking a beating on Monday as rival Teva Pharmaceutical (NYSE: TEVA ) prepares a generic depression drug. According to a filing with the U.S. Securities and Exchange Commission (SEC), Teva Pharmaceutical intends to make its own generic version of Auvelity.
- 02/13/2023
|
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
- TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
- 02/09/2023
|
Teva Pharmaceutical Industries Limited (TEVA) Q4 2022 Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Richard Francis - Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies Jason Gerberry - Bank of America Balaji Prasad - Barclays Elliot Wilbur - Raymond James Christopher Schott - JPMorgan Rishi Parekh - JPMorgan Operator Welcome to the Teva's Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] Please be advised that this conference is being recorded.
- 02/08/2023
|
Why Teva Pharmaceutical Stock Is Sliding Today
- Investors were disappointed with the drugmaker's 2023 outlook.
- 02/08/2023
|
Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026
- These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.
- 02/08/2023
|
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
- Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
- 01/27/2023
|
Is Teva Pharmaceutical Industries (TEVA) a Great Value Stock Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 01/27/2023
|
6 Great Stocks to Buy in 2023 and Hold Forever
- I own all six great businesses and don't plan to sell a single share.
- 01/26/2023
|
Nasdaq Bear Market: 3 Screaming Bargains That Can Double Your Money by 2025
- A 33% plunge in the Nasdaq Composite is the opportune time to scoop up these exceptional deals.
- 01/25/2023
|
3 Dirt Cheap Stocks to Buy in January
- Bargains can easily be found as the new year gets underway.
- 01/14/2023
|
Teva Pharmaceutical Industries Ltd. (TEVA) Presents at 41st Annual J.P.
- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA ) 41st Annual J.P.
- 01/11/2023
|
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Jumps 5.5%: Will It Continue to Soar?
- Teva Pharmaceutical Industries Ltd. (TEVA) witnessed a jump in share price last session on above-average trading volume.
- 01/09/2023
|
2 "Safe" Stocks That Are Anything But
- Sometimes, business models that sound safe still fail to deliver for shareholders.
- 12/30/2022
|
Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
- Shares look to have been undergoing a bottoming pattern for well over three years now. Although near-term EPS revisions have been faltering, Teva's relationship between its valuation and profitability points to an undervalued stock.
- 12/28/2022
|
My Top 5 Portfolio Holdings for 2023
- This mix of growth and value stocks can outperform in a challenging environment.
- 12/21/2022
|
3 Unparalleled Stocks to Buy That Have Never Been This Cheap
- These three leading companies are ripe for the picking and may never be this cheap again.
- 12/05/2022
|
C-Suite Shakeup Pressures Teva Pharmaceutical Stock
- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is down 2.1% at $8.54 at last check, after the company named former Novartis (NVS) and Biogen (BIIB) executive Richard Francis as its new chief executive officer, effective after the retirement of CEO Karen Schultz later this year.
- 11/21/2022
|
TEVA Stock Alert: What to Know About Teva Pharmaceuticals' New CEO
- Teva Pharmaceuticals (NYSE: TEVA ) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. Francis will take over as the president and CEO of Teva Pharmaceuticals starting on Jan. 1, 2023.
- 11/21/2022
|
Teva names former Sandoz chief Richard Francis as new CEO
- Teva Pharmaceutical Industries Ltd. TEVA, +0.93% on Monday said its current CEO Kåre Schultz will retire on Dec. 31.
- 11/21/2022
|
Teva Pharmaceutical: Warren Buffett Likely Made A Mistake Selling Shares
- Teva Pharmaceutical was able to achieve a nationwide settlement to the opioid crisis, proving the ability of the company's management to overcome difficulties. Teva Pharmaceutical's provision for legal settlements and loss contingencies was $4,077 million in Q3 2022, up 103% year-over-year.
- 11/18/2022
|
Adding $100 to These 5 Stocks Would Be a Genius Move Right Now
- You don't need a large pile of cash to begin building wealth on Wall Street.
- 11/09/2022
|
Why Teva Stock Stumbled Again on Friday
- A degree of uncertainty about the company's leadership compounded some rather discouraging recent developments.
- 11/04/2022
|
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
- TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
- 11/04/2022
|
Why Teva Stock Sank On Thursday
- There were two major developments with the company, both of which involved piles of money.
- 11/03/2022
|
Teva Pharmaceutical Industries Limited (TEVA) Q3 2022Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Kare Schultz - President and Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Elliot Wilbur - Raymond James Glen Santangelo - Jefferies Umer Raffat - Evercore Jason Gerberry - Bank of America Denis Reznik - BMO Capital Markets Ashwani Verma - UBS David Amsellem - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Teva's Third Quarter 2022 Financial Results Conference Call.
- 11/03/2022
|
Teva Pharmaceuticals Will Pay Up To $523 Million In New York For Opioid Settlement
- The Israeli company will shell out as much as $4.2 billion nationwide as part of a tentative deal.
- 11/03/2022
|
New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis
- The New York Attorney General's office announced it has secured $523 million from Teva Pharmaceuticals and affiliates for its role in the opioid crisis, effectively marking the end of the state's litigation against opioid manufacturers and distributors not currently in bankruptcy proceedings.
- 11/03/2022
|
FDA warns of Adderall shortage after Teva manufacturing delay
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's warning of an Adderall shortage after Teva experiences a manufacturing delay.
- 10/14/2022
|
What To Do After EU Hits Teva With Antitrust Concerns
- The European Commission's antitrust accusation against Teva is poorly timed. Teva's selling momentum could continue from here.
- 10/10/2022
|
Why Teva Stock Shot More Than 3% Higher Today
- The generic drugs specialist settled one of a number of state lawsuits over its business practices.
- 09/30/2022
|
Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
- Teva is a solid company which faces/faced headwinds from their high debt load and opioid crisis settlement uncertainty. But with most of the settlement uncertainty behind them and their efforts to significantly lower their debt, their current valuation doesn't make sense.
- 09/28/2022
|
Teva Pharm expects to start paying U.S. opioid settlement in 2023 - CEO
- Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday.
- 09/18/2022
|
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike
- The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain.
- 09/18/2022
|
Teva Pharmaceutical: Past Behind And A Promising 2023
- Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 billion, a remarkable sum for a company with a market cap of only $10 billion.
- 09/16/2022
|
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
- The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
- 09/09/2022
|
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
- Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.
- 08/07/2022
|
Why Teva Stock Trounced the Market on Friday
- Bank of America finds its inner bull with the generics producer.
- 08/05/2022
|
Teva Q2 Earnings: 5 Reasons Why Shares Rose By 30%
- Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright.
- 07/28/2022
|
Teva Pharmaceutical Industries Limited's (TEVA) CEO Kare Schultz on Q2 2022 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Ran Meir – Senior Vice President, Head of Investor Relations Kare Schultz – Chief Executive Officer Eli Kalif – Chief Financial Officer Sven Dethlefs – Executive Vice President, North America Commercial Conference Call Participants Balaji Prasad – Barclays Nathan Rich – Goldman Sachs Umer Raffat – Evercore Jason Gerberry – Bank of America Ashwani Verma – UBS Elliot Wilbur – Raymond James Gary Nachman – BMO Capital Markets David Amsellem – Piper Sandler Operator Welcome to the Teva's Second Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode.
- 07/27/2022
|
Teva reaches opioid settlement, Credit Suisse names new CEO, Twitter to hold shareholder vote
- Yahoo Finance anchor Brad Smith reports the latest notable business headlines including pharmaceutical company Teva reaching an opioid settlement, Credit Suisse naming Ulrich Koerner as the company's new CEO, and Twitter holding a shareholder meeting to vote on the $44 billion Elon Musk merger.
- 07/27/2022
|
Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid Deals
- Teva Pharma inked settlement deals worth upward of $4 billion for its role in the opioid crisis, and Teva stock skyrocketed on Wednesday. The post Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid Deals appeared first on Investor's Business Daily.
- 07/27/2022
|
TEVA Stock Surges 24% as Teva Pharmaceuticals Settles Lawsuits
- Source: JHVEPhoto / Shutterstock.com Teva Pharmaceuticals (NYSE: TEVA ) stock is soaring higher on Wednesday after the pharmaceutical company reached a settlement in recent lawsuits. According to recent reports, Teva Pharmaceuticals is prepared to pay a proposed $4.35 billion to settle lawsuits connected to the opioid crisis in the U.S. That covers $3.7 billion in cash to local governments, $1.2 billion worth of opioid overdose treatment naloxone, as well as other payments.
- 07/27/2022
|
Pharma Stock Explodes After Massive Settlement, Earnings
- Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are exploding today, after the drugmaker agreed to pay up to $4.25 billion for its alleged role in the U.S. opioid crisis.
- 07/27/2022
|
Teva Pharmaceutical Soars On $75 Million Opioid Deal In West Virginia
- Teva Pharmaceutical will pay $75 million over 15 years and provide free opioid overdose treatment for 10 years. Teva stock rocketed.
- 07/27/2022
|
Teva's stock jumps 25% after announcing $4.2 billion deal to resolve opioid lawsuits
- Shares of Teva Pharmaceutical Industries Ltd. TEVA, -0.97% soared 25.7% in premarket trading on Wednesday, the day after the company said it will pay $4.25 billion to states, plus an additional $100 million to Native American tribes, over 13 years to resolve most opioid lawsuits it's facing.
- 07/27/2022
|
Why Teva Pharmaceutical Industries Stock Is On Fire Today
- The drugmaker's opioid litigation may soon be resolved.
- 07/27/2022
|
Teva reaches proposed $4.35 billion settlement of US opioid lawsuits
- Teva Pharmaceutical Industries on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleged role in the US opioid epidemic.
- 07/26/2022
|
Teva reaches proposed $4.25 billion settlement of U.S. opioid lawsuits
- Teva Pharmaceutical Industries announced a $4.25 billion proposed nationwide settlement on Tuesday that could resolve thousands of lawsuits over the drugmaker's alleged role in the U.S. opioid epidemic.
- 07/26/2022
|
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
- Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
- 07/26/2022
|
5 Stocks I'm Betting the Farm On
- Despite owning 44 stocks, I have 62.5% of my invested assets in just five companies.
- 07/21/2022
|
With Brighter Outlook, Generics Could Be Ripe for Investment
- Of the top 10 generic drugmakers in 2021, only one scored an increase in share price during the past year. It was Sun Pharmaceutical Industries Ltd.
- 07/18/2022
|
San Francisco reaches $54 million opioid settlement with Teva and Allergan
- Teva Pharmaceutical Industries Inc and AbbVie's Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced.
- 07/12/2022
|
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will
- 06/29/2022
|
2 Buffett Stocks That Outperformed the S&P During the Great Recession
- Are these stocks still good buys today?
- 06/28/2022
|
Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
- The Health Care sector has been relatively strong this year amid stock market volatility. Teva Pharmaceuticals struggles with opioid lawsuits, generic drug issues as shares drift lower.
- 06/19/2022
|
Nasdaq Bear Market: 3 of the Cheapest Stocks You Can Confidently Buy Right Now
- These highly profitable stocks are valued at just three to six times Wall Street's forecast earnings for 2023.
- 06/15/2022
|
Here's A Better Pick Over Abbott Stock
- If we look at stock returns, Abbott's -1% return is better than Teva's -13% change over the last twelve months.
- 05/31/2022
|
Teva, Allergan reach $161.5 million opioid settlement with West Virginia
- (Reuters) -Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said Wednesday.
- 05/25/2022
|
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated,.
- 05/17/2022
|
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
- Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) stock, according to BofA Securities.
- 05/17/2022
|
Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague
- With the broader market tumbling, value stocks are bound to come into focus.
- 05/12/2022
|
Teva's Q1 Results: Is the Stock About to Crash?
- The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
- 05/05/2022
|
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
- TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
- 05/04/2022
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2022 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Ran Meir - Head, IR Kåre Schultz - CEO Eli Kalif - CFO Sven Dethlefs - Head, North America Commercial Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Eric Masane - Evercore ISI Chris Schott - JPMorgan Elliot Wilbur - Raymond James Ronny Gal - Bernstein Gary Nachman - BMO Capital Markets Bhavin Patel - Bank of America Operator Good day, and thank you for standing by, and welcome to Teva's First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 05/03/2022
|
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise
- Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q1 sales reached $3.66 billion, shrinking 8% Y/Y, missing the consensus of $3.75 billion. The decrease is mainly due to lower revenues from generic products in North America and Copaxone, partially offset by higher revenues from.
- 05/03/2022
|
Teva Pharm Q1 profit down, cuts 2022 revenue outlook
- Israel-based Teva Pharmaceutical Industries reported as expected first-quarter profit and trimmed 2022 revenue estimates due to currency fluctuations.
- 05/03/2022
|
Teva shares slide 3% premarket as company swings to a loss and revenue falls
- Teva Pharmaceutical Industries Ltd. shares TEVA, -2.07% slid 3% in premarket trade Tuesday, after the generics company swung to a loss in the first quarter as revenue fell.
- 05/03/2022
|
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
- Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
- 05/02/2022
|
Walgreens, Teva face San Francisco trial over opioid epidemic
- San Francisco will square off on Monday against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
- 04/25/2022
|
Is Teva Pharmaceuticals a Brilliant Contrarian Pick?
- Investing in this generic drugmaker would be a gamble, but there are reasons why it might be worth a look.
- 04/21/2022
|
Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA
- Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone to treat schizophrenia faces rejection from the FDA.
- 04/20/2022
|
FDA Rejects Teva - MedinCell's Schizophrenia Candidate
- Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) U.S. affiliate and MedinCell SA (OTC: MDCLF) have received FDA Complete Response Letter (CRL) regarding TV-46000/mdc-IRM for schizophrenia. The drug candidate is risperidone extended-release injectable suspension for.
- 04/20/2022
|
3 Reasons To Buy Teva At $10
- 3 Reasons To Buy Teva At $10
- 04/07/2022
|
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
- TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2022 financial results on Tuesday, May 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 928338; passcode: 8
- 04/04/2022
|
West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters
- West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE: ABBV) Allergen accountable for causing a "tsunami" of opioid addiction in the.
- 04/04/2022
|
CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report
- Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE: CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic. CVS will shell out $484 million, Teva Pharmaceutical Industries Ltd.
- 03/30/2022
|
Teva stock jumps toward longest win streak in 2 years, after Bernstein analyst turns bullish
- Shares of Teva Pharmaceutical Industries Ltd. TEVA, +5.81% hiked up 5.0% toward a six-week high in afternoon trading Friday, putting them on track for a ninth-straight gain, after Bernstein analyst Aaron Gal turned bullish on the "long suffering" generic drug maker.
- 03/25/2022
|
This Pharma Stock's Luck May Be Changing, Says Analyst
- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock was last seen up 4.7% at $8.55 this morning, following an upgrade from Bernstein.
- 03/25/2022
|
What's Next For Teva Pharmaceutical Stock After A 17% Fall In A Month?
- The price of Teva Pharmaceutical stock has seen a fall of 17% in a month, while it is down 34% in the last year. The shares of generic drug makers have largely underperformed the broader markets over the last year or so, primarily due to concerns around the pricing environment and liabilities.
- 03/16/2022
|
10 Stocks Warren Buffett Is Selling
- Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.
- 02/14/2022
|
TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates
- Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.
- 02/10/2022
|
Teva CEO Kåre Schultz discusses company's latest quarter and opioid settlement
- Teva CEO Kåre Schultz joins 'The Exchange' to discuss Covid's impact on patient behavior.
- 02/09/2022
|
Teva Pharmaceutical Industries Ltd. (TEVA) CEO Kåre Schultz on Q4 2021 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Ltd. (TEVA) CEO Kåre Schultz on Q4 2021 Results - Earnings Call Transcript
- 02/09/2022
|
Why Are Teva Pharmaceutical Shares Trading Higher Today?
- Teva Pharmaceutical Industries Ltd's TEVA Q4 sales reached $4.1 billion, shrinking 8% Y/Y, missing the consensus of $4.29 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/09/2022
|
Teva Pharm Q4 profit rises, sees more growth in key drugs
- Teva Pharmaceutical Industries beat fourth-quarter profit expectations as gains in North American sales of Huntington's disease treatment Austedo and migraine product Ajovy offset declines in generics.
- 02/09/2022
|
Teva stock falls after revenue falls below expectations, full-year profit outlook misses
- Shares of Teva Pharmaceutical Industries Ltd. TEVA, -2.01% shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns.
- 02/09/2022
|
Teva, Texas Enter $225M Opioid Settlement Agreement
- Teva Pharmaceutical Industries Ltd TEVA has reached a settlement worth $225 million to resolve claims the Company fueled an opioid epidemic in Texas. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/07/2022
|
Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?
- Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.
- 01/31/2022
|
Teva: Competent Management Despite Lawsuits And Debts
- Teva: Competent Management Despite Lawsuits And Debts
- 01/28/2022
|
3 Turnaround Stocks That Can Bounce Back Big Time in 2022
- These beaten-down growth and value stocks have all the tools necessary to reverse course.
- 01/19/2022
|
7 Stocks to Buy That Are Nowhere Near Being Overvalued
- These stocks to buy are above their lows and appear overvalued. They have more upside as growth drivers emerge lifting their prospects.
- 01/18/2022
|
Teva Pharmaceutical Industries Limited's (TEVA) CEO Kåre Schultz on 40th Annual JPMorgan Healthcare Conference- Conference Call Transcript
- Teva Pharmaceutical Industries Limited's (TEVA) CEO Kåre Schultz on 40th Annual JPMorgan Healthcare Conference- Conference Call Transcript
- 01/11/2022
|
Teva Suffers Loss In New York's Opioid Trial
- A jury in Suffolk County State Supreme Court found Teva Pharmaceutical Industries Ltd (NYSE: TEVA) contributed to New York's opioid epidemic. Next, the court will hold another trial to determine how much Teva should pay.
- 01/03/2022
|
22 Stocks That Could Double Your Money in 2022
- Triple-digit returns could be just a click of the buy button away.
- 01/03/2022
|
Pot Stocks Closing Out 2021 On a Quiet Note
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up as we round out 2021.
- 12/31/2021
|
Teva's stock swings to a sharp loss after jury finds its U.S. subsidiary violated rights of New Yorkers
- Shares of Teva Pharmaceutical Industries Ltd. TEVA, -4.57% sank 4.6% in afternoon trading Thursday, reversing an earlier gain of as much as 3.1%, after New York Attorney General Letitia James said a jury found that the drug maker's subsidiary Teva Pharmaceuticals USA and violated rights of New Yorkers, as a contributor to the opioid crisis.
- 12/30/2021
|
Jury finds Teva Pharmaceuticals fueled opioid epidemic in New York State
- CNBC's Courtney Reagan reports on falling Teva Pharmaceutical shares after a jury found the company fueled the opioid epidemic in New York.
- 12/30/2021
|
Teva fueled opioid addiction in New York, jury finds
- Teva Pharmaceutical Industries Ltd fueled opioid addiction in New York state, a jury found on Thursday, a setback for a company still facing thousands of other opioid-related lawsuits around the United States.
- 12/30/2021
|
My Top 5 Portfolio Holdings for 2022
- This mix of growth and value stocks should shine over the long run.
- 12/30/2021
|
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
- The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
- 12/29/2021
|
NYSE Traded Teva Pharmaceuticals To Market Cannabis Oils From Cannabit-Tikun Olam In Israel, Palestine, Ukraine
- Cannbit-Tikun Olam (TASE:TKUN) will produce various medical cannabis products for Teva Israel, a marketing arm of Teva Pharmaceuticals (NYSE: TEVA). What Happened The Tel Aviv, Israel-based cannabis company confirmed Monday it has signed a collaboration agreement with Teva, under which it will manufacture THC and CBD-rich oils for Teva.
- 12/27/2021
|
Teva: Bracing For Next Catalyst
- The next catalyst for TEVA is likely a jury verdict in the New York trial. I think this will be negative.
- 12/22/2021
|
Teva: Definitely Undervalued
- Ajovy's sales totaled $108 million in Q3 2021, up 71.4% QoQ and 83.1% Q3 2020. The company's cash flow was $795 million in Q3, up 27.1% QoQ and 57.1% Q3 2021.
- 12/12/2021
|
5 Stocks Buffett and Cathie Wood Both Own
- According to the Aggregated Portfolio of Gurus, a Premium feature of GuruFocus, five stocks Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial) and Catherine Wood (Trades, Portfolio)'s ARK Investment Management ( ARKK , Financial) both own are Amazon.com Inc. ( AMZN , Financial), Snowflake Inc. ( SNOW , Financial), StoneCo Ltd. ( STNE , Financial), Teva Pharmaceutical Industries Ltd.
- 12/09/2021
|
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
- These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
- 12/07/2021
|
2 Popular Healthcare Stocks I'd Avoid at All Costs
- There's an entire galaxy full of better places to invest your money.
- 12/03/2021
|
5 Warren Buffett Stocks Are Screaming Buys in December
- Riding the Oracle of Omaha's coattails is often a moneymaking proposition.
- 12/03/2021
|
Endo: A Win In California But Equity Value Still A Question
- Endo: A Win In California But Equity Value Still A Question
- 11/02/2021
|
TEVA Stock: California Ruling De-Risks Story; Upside To $25
- A recent tentative ruling in the California opioid trial in favor of the pharmaceutical manufacturers should catalyze a nationwide settlement.
- 11/02/2021
|
Why Teva Pharmaceutical Stock Is Jumping Today
- The company won in a California opioid-related lawsuit.
- 11/02/2021
|
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
- Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo for schizophrenia patients who underwent stabilization on oral risperidone. Results showed treatment with TV-46000 (overall, q1m or q2m) significantly prolonged time to relapse, decreased proportions of patients with impending relapse at week 24, and demonstrated a significant increase in proportions maintaining stability.
- 11/01/2021
|
Five Considerations After Teva Pharmaceuticals' Q3 Report
- TEVA stock is down irrationally after its quarterly earnings report. Shares traded at a 2021 forward P/E in the 3 times range.
- 10/31/2021
|
Why Teva Pharmaceutical Industries Fell Today
- The pharmaceutical giant whiffs on both the top and bottom lines in its Q3.
- 10/27/2021
|
We see a stable U.S. market place for our generics, says Teva Pharma CEO
- Meg Tirrell joins 'The Exchange' with Teva Pharmaceuticals CEO Kåre Schultz on the company's most recent earnings report and its guidance for the future.
- 10/27/2021
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2021 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2021 Results - Earnings Call Transcript
- 10/27/2021
|
Teva Has Turned the Corner
- Shareholders of Teva Pharmaceutical Industries ( TEVA , Financial) thave now taken a multi-year beating. Since the company hit an all-time high in 2015 and bit off more than it can chew, over-paying for the Actavis acquisition, the company has gone from bad to worse.
- 10/25/2021
|
Is Biogen stock a buy after Teva settled the Vumerity patent lawsuit?
- On Monday, Biogen Inc. (NASDAQ:BIIB) shares edged higher 1% after Teva Pharmaceutical Industries Ltd (TLV:TEVA) settled the Vumerity lawsuit. The lawsuit claimed that Teva's proposed generic version of Vumerity would violate three Alkermes Plc (NASDAQ:ALKS) patents for the multiple sclerosis drug.
- 10/11/2021
|
Teva Stops Production At U.S. Plant After FDA Concerns: Reports
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has temporarily stopped drug production at its Irvine plant in California to address issues raised by the FDA after a recent inspection. The Company did not specify the issues raised by the agency.
- 10/04/2021
|
Is A Fall Imminent For Teva Stock After Its Recent Rally?
- The price of Teva Pharmaceutical stock has seen a rise of 14% in the last five trading days, while it is up 6% over the last month (twenty-one trading days). The recent rise came after the company announced a settlement with the state of Louisiana for opioid-related claims.
- 10/01/2021
|
Why Teva Pharmaceutical Industries Shot Higher Today
- The company reached a settlement in a legal dispute with the state of Louisiana.
- 09/28/2021
|
Is It Time to Buy Warren Buffett's Lowest-Priced Stock?
- Is Berkshire Hathaway's lowest per-share stock a buy?
- 09/22/2021
|
Is Now the Time to Ditch Pharma Stocks?
- With drug pricing reform on the horizon, investors may want to analyze their allocation.
- 09/21/2021
|
5 Berkshire Hathaway Stocks in Downtrends
- Not everything goes up all the time on Wall Street, and no one expects that. Buyers of value stocks typically are prepared to wait for the longer term to play out.
- 09/17/2021
|
Teva: Cautiously Bullish On 5-Year Prospects
- Teva has faced scandal after scandal which soured investors and the general public alike. Even though I think the $40.5 billion Actavis acquisition was a good move, it leveraged Teva to uncomfortable debt levels.
- 09/17/2021
|
3 Discounted Buffett Stocks to Buy Hand Over Fist in September
- Riding the Oracle of Omaha's coattails has historically been a smart move for investors.
- 09/08/2021
|
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
- The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
- 09/01/2021
|
Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review
- The FDA has accepted Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia. TV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.
- 09/01/2021
|
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
- PARSIPPANY, N.J., TEL AVIV & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration (FDA). The acceptance is based on Phase 3 data from two pivotal studies:
- 08/31/2021
|
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
- The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.
- 08/17/2021
|
Digging into the moves in big cap pharma
- Retailers are on deck to report earnings this week, but some macro headwinds could create uncertainty for the group.
- 08/16/2021
|
Why Teva Pharmaceuticals Has Two A-Products In The Bag
- Why Teva Pharmaceuticals Has Two A-Products In The Bag
- 08/10/2021
|
Teva: Maximum Optimism
- Teva is one of the largest pharmaceutical companies in the world and the second largest generic medicine company (after Viatris) in terms of revenue.
- 08/04/2021
|
TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up
- TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view.
- 07/29/2021
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call Transcript
- 07/28/2021
|
Teva Stock Falls After COVID-19 Impacts Q2 Top And Bottomline; Lowers FY21 Outlook
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) Q2 sales reached $3.9 billion, increasing 1% Y/Y or decreasing 2% in local currency terms, missing the consensus of $4.04 billion. The decrease was mainly due to lower revenues in the North America segment, related primarily to Copaxone and Anda.
- 07/28/2021
|
Teva revenue falls short of estimates, lowers guidance as pandemic continue to weigh
- Teva Pharmaceutical Industries Ltd.'s shares slid 2.5% in premarket trade Wednesday, after the Israeli generics maker missed revenue estimates for the second quarter and lowered guidance, citing the continued impact of the pandemic.
- 07/28/2021
|
Recap: Teva Pharmaceutical Q2 Earnings
- Shares of Teva Pharmaceutical Indus (NYSE:TEVA) fell 2.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.27% year over year to $0.59, which were in line with the estimate of $0.59.
- 07/28/2021
|
Will Teva Stock Rebound After A 10% Fall In A Month?
- We believe that Teva Pharmaceutical stock is a good buying opportunity at the present time. TEVA stock trades near $10 currently and it is, in fact, down 28% from its pre-Covid high of around $13 in Feb 2020 – before the coronavirus pandemic hit the world.
- 07/08/2021
|
Warren Buffett's 6 Worst-Performing Stocks in Q2
- As of March 31, Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK-B) had 48 stocks in its portfolio.
- 07/06/2021
|
What To Do After Teva Stock Falls Below $10 Again
- Teva stock abruptly fell below $10 last week. Markets ignore two key product drivers for free cash flow growth.
- 07/05/2021
|
Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass particulate in a vial of the drug. A follow-up review of the suspect sample turned up two other particles, which have been identified as grey silicone and “translucent, colorless cotton fiber,” a notice on the FDA's website said.
- 07/02/2021
|
Here's How Warren Buffett's Portfolio Jumped Almost 10% in Q2
- The value of Warren Buffett's stock holdings rose by 9.5% between its closing values on March 31 and June 30.
- 07/01/2021
|
New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid
- Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors, urging them to hold the companies liable. Jayne Conroy, representing Suffolk County, also said that the drug distributors - AmerisourceBergen Corp (NYSE: ABC), Cardinal Health Inc (NYSE: CAH), and McKesson Corp (NYSE: MCK) failed to report suspicious opioid orders as required.
- 06/29/2021
|
5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021
- These growth and value stocks are begging to be bought by investors.
- 06/26/2021
|
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
- TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its U.S. launch of the first generic version of twice daily PERFOROMIST®, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. “Teva is pleased to provide patients with first-to-mar
- 06/22/2021
|
Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine
- AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patie
- 06/21/2021
|
Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?
- Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume.
- 06/11/2021
|
3 Buffett Stocks to Buy Hand Over Fist in June
- The Oracle of Omaha has a knack for owning great companies that can make investors rich.
- 06/09/2021
|
Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions
- TORONTO--(BUSINESS WIRE)--Teva Canada's Life Effects website features real-life stories from patients and caregivers about the reality of living with chronic conditions.
- 06/08/2021
|
Teva: $30 Or $0 - Legal Risks Offer Setup For A Strangle Or Straddle
- Without legal risks, Teva would be a compelling long, with ~200% upside potential if the company can meet 2023 targets, which I think is possible. However, legal risks, particularly the lack of a nationwide opioid settlement, exacerbate refinancing risks in 2023, making bankruptcy a material possibility.
- 05/25/2021
|
The Top 5 Trades of Francisco Garcia Parames' Firm
- Francisco Garcia Parames (Trades, Portfolio), founder and leader of Spanish investment firm Cobas Asset Management, disclosed his first-quarter portfolio earlier this week.
- 05/07/2021
|
Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were getting crushed.
- 05/04/2021
|
TEVA Stock: From $10.12 To $10.64 Explanation
- The stock price of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) increased 5.09% as it went from $10.12 to $10.64. This is why it happened.
- 04/29/2021
|
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
- TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. “Teva's fir
- 04/29/2021
|
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
- TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year.
- 04/29/2021
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2021 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2021 Results - Earnings Call Transcript
- 04/28/2021
|
Major COVID-19 Vaccine Makers Reject Teva Pharmaceutical's Offer For Jab Manufacture Help: FT
- Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) CEO said that its offers to help manufacture coronavirus vaccines were turned down by major vaccine makers, despite having production capacity ready to deploy, Kare Schultz, CEO told the Financial Times. Teva has production facilities that can package, and fill and finish, vaccine vials.
- 04/28/2021
|
What's Behind Teva's Mixed Q1 Results
- Increased competition for several of its top products continued to affect the drugmaker's performance in Q1.
- 04/28/2021
|
Exclusive: Teva Pharm unlikely to reach deals to co-produce vaccines -CEO
- Israel's Teva Pharmaceutical Industries is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.
- 04/28/2021
|
Teva's stock gains after it beats earnings expectations
- Shares of Teva Pharmaceutical Industries Ltd. gained 0.6% in premarket trading after the drug maker beat earnings expectations for the first quarter, even though sales of its multiple-sclerosis drug continue to dwindle.
- 04/28/2021
|
J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids
- Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial.
- 04/19/2021
|
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
- 04/14/2021
|
Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate)
- AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK. Introducing Seffalair Spiromax and BroPair Spiromax The launch of
- 04/08/2021
|
Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls
- With the trading day approaching halfway over, the broad markets were trading marginally positive.
- 04/07/2021
|
4 Value Stocks That Can Double in a Biden Bull Market
- Value stocks have historically outperformed during economic recoveries -- and these companies look poised to shine under the new administration.
- 03/21/2021
|
Connect Biopharma Pursues $150 Million U.S. IPO Plan
- Connect Biopharma Pursues $150 Million U.S. IPO Plan
- 03/16/2021
|
Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States
- TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the
- 03/08/2021
|
A Giant Pension Bought Up PG&E, Zoom, and a Stock Elon Musk Loves
- South Korea's National Pension Service started investments in PG&E and Etsy, bought more Zoom stock, and sold most of its Teva position in the fourth quarter.
- 02/28/2021
|
Is Teva Pharmaceuticals a Safe Stock to Buy Now?
- The largest generic drug manufacturer in the world can be bought for pennies on the dollar.
- 02/21/2021
|
2 Stocks I'd Avoid at All Costs
- If you're looking for stability or growth, look elsewhere.
- 02/20/2021
|
TEVA Stock Declines Despite Q4 Earnings and Sales Beat
- TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021.
- 02/11/2021
|
8 Cheap Stocks Under $20 That Could Double
- Even though the market has been on fire recently, that doesn't mean you're too late to pick up cheap stocks under $20 with 2x (or more) potential. The post 8 Cheap Stocks Under $20 That Could Double appeared first on InvestorPlace.
- 02/11/2021
|
Teva in Talks to Help Make Covid Vaccines, CEO Says
- Feb.10 -- Teva Pharmaceutical Industries Ltd. Chief Executive Officer Kare Schultz discusses the company's plans to produce and distribute Covid-19 vaccines and says Teva is ready to settle thousands of opioid lawsuits.
- 02/10/2021
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q4 2020 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q4 2020 Results - Earnings Call Transcript
- 02/10/2021
|
Teva Pharmaceuticals CEO on the Covid-19 vaccine rollout in Israel
- Teva Pharmaceuticals CEO Kare Schultz joins "Squawk on the Street" to discuss the rollout of Covid-19 vaccines in Israel. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
- 02/10/2021
|
TEVA Q4 Earnings & Sales Beat Estimates, Stock Rises
- TEVA beats earnings and sales for fourth-quarter 2020. It issues its financial guidance for 2021.
- 02/10/2021
|
Teva's stock rallies 2% on earnings
- Shares of Teva Pharmaceutical Industries Ltd. gained 2.7% in premarket trading on Wednesday after the drugmaker beat expectations for revenue and adjusted earnings per share in the final quarter of 2020.
- 02/10/2021
|
Recap: Teva Pharmaceutical Q4 Earnings
- Shares of Teva Pharmaceutical Indus (NYSE:TEVA) moved higher by 3.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 9.68% over the past year to $0.68, which beat the estimate of $0.63.
- 02/10/2021
|
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 02/09/2021
|
TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
- On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.
- 02/08/2021
|
5 Deeply Discounted Stocks to Buy for a Biden Bull Market
- The conditions are ripe for a strong bull market to take shape under the new administration, and these ultracheap stocks could be direct beneficiaries.
- 01/31/2021
|
ITEQ Is A Way To Invest In Israeli Innovation
- ITEQ Is A Way To Invest In Israeli Innovation
- 01/19/2021
|
3 Turnaround Stocks That Will Make You Richer in 2021
- Things are looking up for these beaten-down value plays in the new year.
- 01/17/2021
|
Teva Stock Pops on Generic NuvaRing® Announcement
- The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are up 0.4% at $11.54 this morning, after the company announced plans to launch a generic version of Merck's (MRK) birth control device known as the NuvaRing®.
- 01/15/2021
|
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 39th Annual JP Morgan Healthcare Conference Transcript
- Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 39th Annual JP Morgan Healthcare Conference Transcript
- 01/13/2021
|
7 Stocks That Could Make You a Millionaire
- With proper research and long-term investing, $1 million can easily be in reach. Check out these stocks that could make you a millionaire.
- 01/12/2021
|
5 Value Stocks That Will Make You Richer in 2021
- Bargains are plentiful for value investors in the new year.
- 01/09/2021
|
5 Buffett Stocks to Buy Hand Over Fist in 2021
- These time-tested Buffett holdings can pump up your portfolio.
- 01/06/2021
|
4 Warren Buffett Stocks He Should Sell
- Warren Buffett stocks have been a mixed bag during this bull market. These four names are the weakest in Berkshire's portfolio.
- 01/05/2021
|
8 Stocks That Could Double Your Money in 2021
- Triple-digit returns could be just a click of the buy button away.
- 01/04/2021
|
My Top 5 Portfolio Holdings for 2021
- This Fool is counting on five growth and value stocks to power his portfolio higher in the new year.
- 12/29/2020
|
3 of the Biggest Bargains in Buffett's Portfolio
- There's something for every type of value investor.
- 12/17/2020
|
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $TEVA #TEVA--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Teva Pharmaceuticals Industries Limited
- 11/23/2020
|
5 Warren Buffett Stocks To Buy For Under $25
- Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B) CEO Warren Buffett is one of the world's richest people, with a net worth of around $86 billion. Unfortunately for small retail investors who want to follow in Buffett's footsteps, buying even one share of Berkshire Hathaway is rather pricey.
- 11/20/2020
|
MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited (NYSE: TEVA) ("Teva" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18, 2020,...
- 11/20/2020
|
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited (NYSE: TEVA) ("Teva" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18,...
- 11/19/2020
|
Teva Shareholder Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 18, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/18/2020
|
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceuticals Industries Limited ("Teva" or "the Company") (NYSE: TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 29, 2015 and August 18,...
- 11/18/2020
|
Teva Deadline Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 17, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/17/2020
|
Teva Lead Plaintiff Deadline Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 15, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/15/2020
|
ROSEN, A LEADING AND RESPECTED LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA
- NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important...
- 11/14/2020
|
Teva Update
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 14, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/14/2020
|
Teva Shareholder Notice
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 11, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/11/2020
|
Rosen, Leading Trial Attorneys, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action - TEVA
- New York, New York--(Newsfile Corp. - November 11, 2020) - Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.To join the Teva...
- 11/11/2020
|
Teva Shareholder Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 10, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/10/2020
|
Teva Class Action Reminder
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 8, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/08/2020
|
ROSEN, A TOP RANKED FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA
- New York, New York--(Newsfile Corp. - November 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.To join the Teva class...
- 11/07/2020
|
Teva Shareholder Notice
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 7, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/07/2020
|
Teva Shareholder Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 5, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/05/2020
|
Teva Pharmaceutical Industries Ltd (TEVA) CEO Kare Schultz on Q3 2020 Results - Earnings Call Transcript
- Teva Pharmaceutical Industries Ltd (TEVA) CEO Kare Schultz on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Generic Pharma Behemoth Skids As Earnings Stall, Sales Lag Forecasts
- Early Thursday, Teva Pharmaceutical reported adjusted earnings of 58 cents per share on $3.98 billion in sales for its third quarter ended Sept. 30. In response, Teva stock slipped.
- 11/05/2020
|
TEVA DEADLINE ALERT
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 4, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/04/2020
|
Teva Deadline Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 2, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 11/02/2020
|
Miller Value Partners is Betting on Teva Pharmaceutical Industries (TEVA) Stock
- Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 8.93% in the same quarter. You should check out Miller Value Partners' top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.
- 11/02/2020
|
ROSEN, A LEADING LAW FIRM, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA
- NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important...
- 10/30/2020
|
Rosen, Top Ranked Investor Counsel, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $500K to Contact the Firm - TEVA
- New York, New York--(Newsfile Corp. - October 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds the purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the "Class Period"), of the important November 23, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.To join the Teva class...
- 10/28/2020
|
4 Top Value Stocks on Sale to Buy Right Now
- Bargains abound for long-term investors.
- 10/28/2020
|
Teva Shareholder Alert
- Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 27, 2020) - If you suffered losses exceeding $50,000 investing in Teva stock or options between October 29, 2015 and August 18, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/TEVA or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
- 10/27/2020
|
